# Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

> **NCT01239797** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 646 (actual)

## Conditions studied

- Lymphoma
- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Dexamethasone (Oral)
- **DRUG:** Dexamethasone (IV)
- **BIOLOGICAL:** Elotuzumab (BMS-901608; HuLuc63)

## Key facts

- **NCT ID:** NCT01239797
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-20
- **Primary completion:** 2014-09-02
- **Final completion:** 2021-04-21
- **Target enrollment:** 646 (ACTUAL)
- **Last updated:** 2022-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01239797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01239797, "Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01239797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*